Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:GWPH NASDAQ:IONS NASDAQ:SRPT NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$28.95+1.0%$20.23$9.57▼$31.13$4.03B12.04 million shs577,878 shsGWPHGW Pharmaceuticals$218.96$218.59$87.07▼$219.57$6.86B2.15899,771 shsN/AIONSIonis Pharmaceuticals$61.50+0.7%$46.18$23.95▼$64.71$9.80B0.281.93 million shs524,115 shsSRPTSarepta Therapeutics$18.37+5.2%$17.75$10.41▼$138.81$1.80B0.496.32 million shs3.64 million shsUTHRUnited Therapeutics$402.72-0.1%$320.79$266.98▼$436.95$18.19B0.62563,518 shs143,185 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-3.53%+5.52%+39.79%+84.97%+33.41%GWPHGW Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IONSIonis Pharmaceuticals-3.26%+0.16%+39.56%+69.02%+44.82%SRPTSarepta Therapeutics+0.46%-0.74%-19.90%-18.97%-85.98%UTHRUnited Therapeutics-0.47%+2.15%+28.74%+40.52%+18.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$28.95+1.0%$20.23$9.57▼$31.13$4.03B12.04 million shs577,878 shsGWPHGW Pharmaceuticals$218.96$218.59$87.07▼$219.57$6.86B2.15899,771 shsN/AIONSIonis Pharmaceuticals$61.50+0.7%$46.18$23.95▼$64.71$9.80B0.281.93 million shs524,115 shsSRPTSarepta Therapeutics$18.37+5.2%$17.75$10.41▼$138.81$1.80B0.496.32 million shs3.64 million shsUTHRUnited Therapeutics$402.72-0.1%$320.79$266.98▼$436.95$18.19B0.62563,518 shs143,185 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-3.53%+5.52%+39.79%+84.97%+33.41%GWPHGW Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IONSIonis Pharmaceuticals-3.26%+0.16%+39.56%+69.02%+44.82%SRPTSarepta Therapeutics+0.46%-0.74%-19.90%-18.97%-85.98%UTHRUnited Therapeutics-0.47%+2.15%+28.74%+40.52%+18.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 3.00Buy$43.1450.29% UpsideGWPHGW Pharmaceuticals 0.00N/AN/AN/AIONSIonis Pharmaceuticals 2.81Moderate Buy$67.8811.39% UpsideSRPTSarepta Therapeutics 2.07Hold$39.32115.52% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$438.859.99% UpsideCurrent Analyst Ratings BreakdownLatest ARWR, UTHR, IONS, SRPT, and GWPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025SRPTSarepta TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.009/10/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$405.00 ➝ $525.009/9/2025SRPTSarepta TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$12.00 ➝ $15.009/5/2025UTHRUnited TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$510.00 ➝ $575.009/5/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$400.00 ➝ $500.009/4/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$415.00 ➝ $560.009/4/2025IONSIonis PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$70.00 ➝ $80.009/3/2025IONSIonis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$69.00 ➝ $84.009/3/2025IONSIonis PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$40.00 ➝ $45.009/3/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$58.00 ➝ $78.009/3/2025IONSIonis PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$40.00 ➝ $70.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$3.55M1,118.04N/AN/A$1.54 per share18.64GWPHGW Pharmaceuticals$311.33M22.05$0.01 per share18,588.22$23.48 per share9.33IONSIonis Pharmaceuticals$705M13.78N/AN/A$3.73 per share16.34SRPTSarepta Therapeutics$1.90B0.94$2.56 per share7.14$15.99 per share1.14UTHRUnited Therapeutics$2.88B6.25$27.96 per share14.27$144.34 per share2.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)GWPHGW Pharmaceuticals-$9.02M-$0.24N/A608.22N/A-11.05%-7.46%-6.13%N/AIONSIonis Pharmaceuticals-$453.90M-$1.84N/AN/AN/A-28.25%-45.29%-8.99%11/5/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A1.67N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.6215.5414.516.1740.36%18.73%16.49%10/29/2025 (Estimated)Latest ARWR, UTHR, IONS, SRPT, and GWPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 million7/30/2025Q2 2025IONSIonis Pharmaceuticals$0.19$0.70+$0.51$0.70$270.90 million$452.00 million7/30/2025Q2 2025UTHRUnited Therapeutics$6.80$6.41-$0.39$6.41$802.13 million$798.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AGWPHGW PharmaceuticalsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.394.874.87GWPHGW Pharmaceuticals0.015.134.31IONSIonis Pharmaceuticals0.992.872.86SRPTSarepta Therapeutics0.842.891.81UTHRUnited TherapeuticsN/A7.266.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%GWPHGW Pharmaceuticals81.00%IONSIonis Pharmaceuticals93.86%SRPTSarepta Therapeutics86.68%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%GWPHGW Pharmaceuticals3.10%IONSIonis Pharmaceuticals2.71%SRPTSarepta Therapeutics7.60%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableGWPHGW Pharmaceuticals1,16131.35 millionN/AOptionableIONSIonis Pharmaceuticals1,069159.39 million155.07 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableARWR, UTHR, IONS, SRPT, and GWPH HeadlinesRecent News About These CompaniesUnited Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum3 hours ago | pharmiweb.comPSwedbank AB Decreases Stock Position in United Therapeutics Corporation $UTHRSeptember 15 at 5:27 AM | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by Integrated Wealth Concepts LLCSeptember 15 at 3:30 AM | marketbeat.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Purchases 25,289 Shares of United Therapeutics Corporation $UTHRSeptember 15 at 3:09 AM | marketbeat.comFY2025 EPS Estimates for UTHR Raised by Cantor FitzgeraldSeptember 14 at 6:34 AM | marketbeat.comInspire Investing LLC Sells 1,237 Shares of United Therapeutics Corporation $UTHRSeptember 14 at 5:56 AM | marketbeat.comUTHR FY2025 EPS Forecast Lifted by Cantor FitzgeraldSeptember 14 at 2:29 AM | americanbankingnews.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $1,588,920.00 in StockSeptember 13 at 8:34 PM | marketbeat.comFY2026 EPS Estimates for UTHR Increased by Cantor FitzgeraldSeptember 13 at 7:54 AM | marketbeat.comAcadian Asset Management LLC Acquires 169,010 Shares of United Therapeutics Corporation $UTHRSeptember 13 at 5:35 AM | marketbeat.comFred Alger Management LLC Makes New $256,000 Investment in United Therapeutics Corporation $UTHRSeptember 13 at 4:08 AM | marketbeat.comEquities Analysts Offer Predictions for UTHR FY2026 EarningsSeptember 13 at 2:43 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Director Sells $280,203.00 in StockSeptember 12, 2025 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 4,560 Shares of StockSeptember 12, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) COO Sells $1,961,050.00 in StockSeptember 12, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,000 SharesSeptember 12, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) COO Sells $4,520,538.75 in StockSeptember 12, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock PriceSeptember 12, 2025 | marketbeat.com21,112 Shares in United Therapeutics Corporation $UTHR Acquired by Capital Impact Advisors LLCSeptember 12, 2025 | marketbeat.comMartine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) StockSeptember 12, 2025 | insidertrades.comUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society CongressSeptember 12, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMedtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Archer's Flight Milestones & Defense Wins Excite Wall Street By Jeffrey Neal Johnson | August 20, 2025Nextracker Stock Rockets as AI and Solar Tailwinds AlignBy Thomas Hughes | August 21, 2025Toll Brothers: A Great Buy and Hold Stock With Risks in 2025By Thomas Hughes | August 21, 2025Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4By Leo Miller | August 18, 2025ARWR, UTHR, IONS, SRPT, and GWPH Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$28.95 +0.28 (+0.98%) As of 12:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.GW Pharmaceuticals NASDAQ:GWPHGW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.Ionis Pharmaceuticals NASDAQ:IONS$61.50 +0.40 (+0.65%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Sarepta Therapeutics NASDAQ:SRPT$18.37 +0.90 (+5.15%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.United Therapeutics NASDAQ:UTHR$402.72 -0.40 (-0.10%) As of 12:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
